A Phase 2 interventional study of Daratumumab and Bortezomib in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 64 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Multiple Myeloma by Johnson & Johnson — 13 open to participants now, 33 under way, 12 of them phase 3. Multiple Myeloma · Johnson & Johnson.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 25th largest by enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2018, is one of 32 in phase 2, and was the 76th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →13 of the 126 studies in Multiple Myeloma by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Australia, Czechia, France and 11 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 7 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Australia, Brazil and 15 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Australia, Brazil and 12 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Australia, Spain
Ages 18–80
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 37 · Phase 3 36 · Phase 4 4
First in 1995; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 265 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 125 across the 100 interventional studies, 255 across the 18 observational. Of the 82 that completed or were terminated, 33 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
9 of the studies in Multiple Myeloma by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05455320Phase 3Janssen Research & Development, LLCA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | 2027-07-30 |
| NCT07030517Johnson & Johnson Private LimitedA Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | 2027-02-12 |
| NCT04133636Janssen Research & Development, LLCA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | 2027-02-26 |
| NCT04108195Janssen Research & Development, LLCA Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | 2027-04-07 |
| NCT05652335Janssen Research & Development, LLCA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | 2027-04-19 |
Add all 9 to your calendar (.ics) → With an account.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate (ORR) or very good partial response (VGPR) or better rate.
The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected for albumin. Safety will be measured by adverse events, laboratory test results, electrocardiogram (ECGs), vital sign measurements, physical examination findings, SC injection-site assessments, and assessment of Eastern Cooperative Oncology Group (ECOG) performance status score. Study will consist of 3 phases (screening, treatment and follow-up) and duration of study is approximately 3 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Measurable, secretory disease as defined by any of the following:
Meets one of the sets of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive daratumumab 1800 milligram (mg) by subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligram per square meter (mg/m\^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.
Drug: Daratumumab · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone
Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1 then on Days 1 and 22 in Cycles 2 to 9 and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; bortezomib 1.3 mg/m\^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m\^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m\^2 orally on Days 1 to 4 of cycles 1 to 9.
Drug: Daratumumab · Drug: Bortezomib · Drug: Melphalan · Drug: Prednisone
Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or end of study.
Drug: Daratumumab · Drug: Lenalidomide · Drug: Dexamethasone
Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days) then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; Carfilzomib 20 mg/m\^2 intravenously (IV) on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or IV weekly for Cycles 1-9 then on Days 1, 8, 15 of each cycle for Cycles 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study.
Drug: Daratumumab · Drug: Dexamethasone · Drug: Carfilzomib
Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
Bortezomib will be administered as 1.3 mg/m\^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.
Melphalan will be administered as 9 mg/m\^2 orally in Cycles 1 to 9.
Prednisone will be administered as 60 mg/m\^2 orally in cycles 1 to 9.
Carfilzomib will be administered as 20 mg/m\^2 IV on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR)
ORR was defined as the percentage of participants who achieved partial response (PR) or better according to international myeloma working group (IMWG) criteria. IMWG criteria for PR: greater than or equal to (\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to less than (\<) 200 milligrams (mg) per 24 hours, If the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.
Time frame: Up to 2 years 3 months
D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response
VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response \[sCR\]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.
Time frame: Up to 2 years and 3 months
Maximum Observed Serum Concentration (Cmax) of Daratumumab
Cmax was defined as maximum serum concentration observed following daratumumab administration. Each cycle for: D-VRd cohort is of 21 days, D-VMP cohort is of 42 days and D-Rd and D-Kd cohorts is of 28 days. Each cohort have a treatment period of 84 days.
Time frame: D-VRd: Day 4 of Cycles 1 and 4 and post treatment at Week 8; D-VMP: Day 4 of Cycles 1 and 2 and post treatment at Week 8; D-Rd and D-Kd: Day 4 of Cycles 1 and 3 and post treatment at Week 8
Percentage of Participants With Infusion-Related Reactions (IRRs)
Percentage of Participants with IRRs were reported. The administration-related systemic reactions are referred to as IRRs.
Time frame: For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With VGPR or Better Response
VGPR or better rate was defined as the percentage of participants who achieved VGPR or CR (including sCR) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.
Time frame: From baseline up to 2 years 7 months
D-VRd Cohort: Overall Response Rate (ORR)
ORR was defined as the percentage of participants who achieved a PR or better, IMWG criteria, during the study or during follow up. IMWG criteria for PR \>= 50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.
Time frame: Up to 2 years and 3 months
Percentage of Participants With CR or Better Response
CR or better rate was defined as the percentage of participants with a CR or better response (that is, CR and sCR) as per IMWG criteria. CR: as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow; sCR: CR plus normal FLC ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.
Time frame: For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
D-VMP, D-Rd and D-Kd Cohorts: Duration of Response (DOR)
DOR was defined as the time from the date of initial documented response (PR or better response) to the date of first documented evidence of progressive disease (PD) or death due to PD. PD is defined as an increase of 25% from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>=0.5 gram per deciliter \[g/dL\] and \>=200 mg/24 hours respectively); only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \>10 mg/dL); definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
Time frame: From baseline up to 2 years 7 months
Percentage of Participants With Anti-Daratumumab Antibodies
Percentage of participants with antibodies to daratumumab were reported.
Time frame: For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
Percentage of Participants With Anti-rHuPH20 Antibodies
Percentage of participants with antibodies to rHuPH20 were reported.
Time frame: For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months
D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With Minimal Residual Disease (MRD) Negative Rate
MRD negativity rate was defined as the percentage of participants who were considered MRD negative after MRD testing at any timepoint after the first dose by bone marrow aspirate. MRD negativity rate was assessed by next-generation sequencing at a threshold of \<10\^5.
Time frame: Up to 2 years and 3 months
| Milestone | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|---|
| Started | 67 | 67 | 65 | 66 |
| Completed | 66 | 19 | 14 | 15 |
| Not completed | 1 | 48 | 51 | 51 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 4 | 5 | 5 |
| Withdrew: Death | 1 | 3 | 4 | 5 |
| Withdrew: Data collection ended | 0 | 41 | 41 | 40 |
ORR was defined as the percentage of participants who achieved partial response (PR) or better according to international myeloma working group (IMWG) criteria. IMWG criteria for PR: greater than or equal to (\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to less than (\<) 200 milligrams (mg) per 24 hours, If the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.
| percentage of participants | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|
| D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR) | 88.1 (79.5 to 93.9) | 90.8 (82.6 to 95.9) | 84.8 (75.7 to 91.5) |
VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response \[sCR\]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.
| percentage of participants | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) |
|---|---|
| D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response | 71.6 (61.2 to 80.6) |
Cmax was defined as maximum serum concentration observed following daratumumab administration. Each cycle for: D-VRd cohort is of 21 days, D-VMP cohort is of 42 days and D-Rd and D-Kd cohorts is of 28 days. Each cohort have a treatment period of 84 days.
| micrograms per milliliter (mcg/mL) | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|---|
| Cycle 1 Day 4 | 100 ± 48.5 | 98.6 ± 51.6 | 108 ± 49.9 | 137 ± 56.7 |
| Cycle 2 Day 4 | — | 612 ± 256 | — | — |
| Cycle 3 Day 4 | — | — | 648 ± 238 | 869 ± 274 |
| Cycle 4 Day 4 | 746 ± 275 | — | — | — |
| Post-treatment Phase Week 8 | 263 ± 190 | 162 ± NA | — | 49.3 ± 109 |
Percentage of Participants with IRRs were reported. The administration-related systemic reactions are referred to as IRRs.
| percentage of participants | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|---|
| Percentage of Participants With Infusion-Related Reactions (IRRs) | 9.0 (4.0 to 16.9) | 9.0 (4.0 to 16.9) | 4.6 (1.3 to 11.5) | 4.5 (1.3 to 11.3) |
VGPR or better rate was defined as the percentage of participants who achieved VGPR or CR (including sCR) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \<5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.
| percentage of participants | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|
| D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With VGPR or Better Response | 77.6 (67.6 to 85.7) | 80.0 (70.1 to 87.7) | 77.3 (67.2 to 85.4) |
ORR was defined as the percentage of participants who achieved a PR or better, IMWG criteria, during the study or during follow up. IMWG criteria for PR \>= 50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.
| percentage of participants | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) |
|---|---|
| D-VRd Cohort: Overall Response Rate (ORR) | 97.0 (90.9 to 99.5) |
CR or better rate was defined as the percentage of participants with a CR or better response (that is, CR and sCR) as per IMWG criteria. CR: as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow; sCR: CR plus normal FLC ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.
| percentage of participants | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|---|
| Percentage of Participants With CR or Better Response | 16.4 (9.5 to 25.7) | 55.2 (44.5 to 65.6) | 50.8 (39.9 to 61.5) | 42.4 (32.1 to 53.3) |
DOR was defined as the time from the date of initial documented response (PR or better response) to the date of first documented evidence of progressive disease (PD) or death due to PD. PD is defined as an increase of 25% from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>=0.5 gram per deciliter \[g/dL\] and \>=200 mg/24 hours respectively); only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \>10 mg/dL); definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
| months | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|
| D-VMP, D-Rd and D-Kd Cohorts: Duration of Response (DOR) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Percentage of participants with antibodies to daratumumab were reported.
| percentage of participants | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|---|
| Percentage of Participants With Anti-Daratumumab Antibodies | 0 | 0 | 0 | 0 |
Percentage of participants with antibodies to rHuPH20 were reported.
| percentage of participants | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|---|
| Percentage of Participants With Anti-rHuPH20 Antibodies | 6.1 | 3.1 | 4.8 | 4.7 |
MRD negativity rate was defined as the percentage of participants who were considered MRD negative after MRD testing at any timepoint after the first dose by bone marrow aspirate. MRD negativity rate was assessed by next-generation sequencing at a threshold of \<10\^5.
| percentage of participants | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|
| D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With Minimal Residual Disease (MRD) Negative Rate | 25.4 (16.9 to 35.6) | 21.5 (13.5 to 31.6) | 27.3 (18.4 to 37.7) |
Collected over For D-VRD Arm: Baseline up to 2 years 3 months; For D-VMP, D-Rd and D-Kd Arms: Baseline up to 2 years 7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | 1/67 (1.5%) | 19/67 (28.4%) | 67/67 (100%) |
| D + Bortezomib + Melphalan + Prednisone (D-VMP) | 3/67 (4.5%) | 30/67 (44.8%) | 67/67 (100%) |
| Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | 4/65 (6.2%) | 37/65 (56.9%) | 65/65 (100%) |
| Daratumumab + Carfilzomib + Dexamethasone (D-Kd) | 5/66 (7.6%) | 22/66 (33.3%) | 66/66 (100%) |
| Event | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/67 | 6/67 | 9/65 | 3/66 |
| DiarrhoeaGastrointestinal disorders | 0/67 | 1/67 | 5/65 | 0/66 |
| PyrexiaGeneral disorders | 4/67 | 5/67 | 3/65 | 2/66 |
| InfluenzaInfections and infestations | 0/67 | 1/67 | 4/65 | 1/66 |
| NeutropeniaBlood and lymphatic system disorders | 0/67 | 0/67 | 3/65 | 0/66 |
| Cardiac FailureCardiac disorders | 0/67 | 2/67 | 3/65 | 1/66 |
| Lower Respiratory Tract InfectionInfections and infestations | 1/67 | 0/67 | 3/65 | 0/66 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/67 | 0/67 | 3/65 | 0/66 |
| Acute Kidney InjuryRenal and urinary disorders | 0/67 | 2/67 | 3/65 | 0/66 |
| SepsisInfections and infestations | 0/67 | 0/67 | 2/65 | 1/66 |
| Event | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 25/67 | 30/67 | 44/65 | 15/66 |
| ThrombocytopeniaBlood and lymphatic system disorders | 25/67 | 38/67 | 23/65 | 34/66 |
| DiarrhoeaGastrointestinal disorders | 16/67 | 23/67 | 32/65 | 20/66 |
| AnaemiaBlood and lymphatic system disorders | 12/67 | 30/67 | 26/65 | 25/66 |
| ConstipationGastrointestinal disorders | 26/67 | 30/67 | 21/65 | 6/66 |
| Peripheral Sensory NeuropathyNervous system disorders | 28/67 | 26/67 | 14/65 | 7/66 |
| InsomniaPsychiatric disorders | 12/67 | 16/67 | 13/65 | 23/66 |
| HypertensionVascular disorders | 1/67 | 10/67 | 8/65 | 23/66 |
| NauseaGastrointestinal disorders | 12/67 | 23/67 | 8/65 | 17/66 |
| PyrexiaGeneral disorders | 22/67 | 22/67 | 16/65 | 14/66 |
| Age, Continuous(years) | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) | Total |
|---|---|---|---|---|---|
| Mean | 57.3 ± 9.47 | 74.9 ± 4.54 | 66.8 ± 9.58 | 61 ± 9.77 | 65 ± 10.87 |
| Sex: Female, Male(Participants) | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) | Total |
|---|---|---|---|---|---|
| Female | 19 | 36 | 20 | 32 | 107 |
| Male | 48 | 31 | 45 | 34 | 158 |
| Ethnicity (NIH/OMB)(Participants) | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 6 | 0 | 7 | 16 |
| Not Hispanic or Latino | 34 | 39 | 45 | 43 | 161 |
| Unknown or Not Reported | 30 | 22 | 20 | 16 | 88 |
| Race (NIH/OMB)(Participants) | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 5 | 0 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 1 | 2 | 2 | 10 |
| White | 38 | 46 | 45 | 48 | 177 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 24 | 15 | 18 | 16 | 73 |
| Region of Enrollment(Participants) | Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd) | D + Bortezomib + Melphalan + Prednisone (D-VMP) | Daratumumab + Lenalidomide + Dexamethasone (D-Rd) | Daratumumab + Carfilzomib + Dexamethasone (D-Kd) | Total |
|---|---|---|---|---|---|
| BRAZIL | 1 | 4 | 0 | 0 | 5 |
| CZECH REPUBLIC | 4 | 4 | 15 | 0 | 23 |
| FRANCE | 26 | 21 | 17 | 15 | 79 |
| GERMANY | 0 | 0 | 0 | 19 | 19 |
| ISRAEL | 0 | 7 | 14 | 0 | 21 |
| JAPAN | 0 | 4 | 0 | 0 | 4 |
| SPAIN | 11 | 19 | 0 | 25 | 55 |
| UNITED KINGDOM | 9 | 8 | 12 | 0 | 29 |
| UNITED STATES | 16 | 0 | 7 | 7 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2018 to primary completion in Aug 2020, 27 months.
Results were first posted in Jan 2022, 1 year 5 months after primary completion. A results delay was requested in Aug 2021.
Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 27 months is below that.
Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Research & Development, LLC →